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Combining lisinopril and L-arginine slows disease progression
and reduces endothelin-1 in passive Heymann nephritis.
Background. Despite angiotensin-converting enzyme (ACE)
inhibition is a very powerful therapy, it may not be uniformly
renoprotective in patients with proteinuric nephropathies who
might refer late in the course of the disease. In accelerated
passive Heymann nephritis (PHN), a severe rat model of human
membranous nephropathy, with proteinuria and increased uri-
nary excretion of endothelin-1 (ET-1), early treatment with an
ACE inhibition limited proteinuria as well as the exuberant
formation of renal ET-1, while late treatment reduced urinary
proteins not to a significant extent. Since biologic effects and
production of ET-1 within the kidney are counteracted by nitric
oxide, we studied the effect of combining lisinopril and l-argi-
nine, the natural precursor of nitric oxide, starting late in the
disease.
Methods. Uninephrectomized PHN rats were divided in four
groups (N 10) and daily given orally: vehicle; 1.25 g/L l-arginine;
40 mg/L lisinopril; and l-arginine lisinopril. Treatments started
at 2 months, when rats had massive proteinuria, until 9 months.
Six normal rats served as control.
Results. Increase in systolic blood pressure was significantly
limited by l-arginine. Lisinopril alone and the combination were
more effective. Renal function impairment was not affected
by l-arginine, partially ameliorated by ACE inhibitor and nor-
malized by the combined therapy. In rats given l-arginine,
proteinuria levels were similar to vehicle. ACE inhibitor kept
proteinuria at values comparable to pretreatment and numeri-
cally lower than vehicle. Addition of l-arginine to lisinopril
was more effective, with values significantly lower than vehicle.
Glomerular and tubular changes were limited by the ACE
inhibitor and further ameliorated by the combined therapy.
Exaggerated urinary ET-1 of PHN was reduced by 23% and
40% after l-arginine and lisinopril, respectively, and by 62%
with the combination. Defective urinary excretion of cyclic
guanosine monophosphate (cGMP) was partially restored by
lisinopril, while normalized by the combined therapy.
Conclusion. Combining l-arginine with ACE inhibitors
would represent a novel strategy for patients with severe ne-
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phropathy not completely responsive to ACE inhibition. Re-
storing the nitric oxide/ET-1 balance could be of benefit in
halting renal disease progression.
Pharmacologic inhibition of renin-angiotensin system
(RAS) with angiotensin-converting enzyme (ACE) in-
hibitors has been shown in landmark experimental and
clinical studies to limit proteinuria and attenuate decline
in renal function inexorably associated with chronic renal
diseases [1, 2]. These effects have been attributed to
the control of systemic and intraglomerular hypertension
along with the ability of this class of drugs to limit excess
protein ultrafiltration and its deleterious consequences
[3]. When given soon after disease induction, ACE inhi-
bition consistently limits hypertension, proteinuria, and
renal injury in virtually all animal models of renal disease
[4–7]. By contrast, when treatment starts late in the course
of the disease at the stage of overt nephropathy, drugs
that antagonize RAS are not uniformly effective [8–10].
Most patients with proteinuric nondiabetic, or diabetic
renal disease are actually referred late or very late to
the nephrologist, and in such circumstances treatment
with ACE inhibitors is of little value, if anything, to control
urinary proteins and influence disease progression. To
model the human condition of advanced nephropathy,
we set up accelerated passive Heymann nephritis (PHN),
mimicking membranous nephropathy, in which the renal
damage is worsened by unilateral nephrectomy, and
ACE inhibitors are not consistently effective [11]. This
setting was instrumental to verify whether combined
treatments may still retain therapeutic effectiveness when
ACE inhibition is no longer enough.
A role for nitric oxide in limiting progressive kidney
disease has recently emerged. Specifically, inhibition of
nitric oxide synthesis by L-NAME worsened the course
of the disease [12–15], while maneuvers that enhance
nitric oxide were renoprotective [16–18]. A direct ap-
proach to increasing nitric oxide synthesis is to provide
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additional substrate to the endothelium-specific isoform
of nitric oxide synthase (eNOS), a constitutive enzyme
responsible for the basal production of nitric oxide. The
semiessential amino acid l-arginine serves as the princi-
pal substrate for the enzyme, in that NOS catalyzes the
5-electron oxidation of l-arginine to l-citrulline and pro-
duces stoichiometric amounts of nitric oxide in this pro-
cess [19]. Beneficial effects of dietary intervention with
l-arginine have been reported in experimental renal dis-
ease [20]. l-arginine supplementation has been shown to
improve renal hemodynamics [17] and protect renal tissue
from inflammatory damage by decreasing macrophage
infiltration [21]. Studies have documented that l-arginine
may affect cell proliferation [16] and deposition of colla-
gen [22]. The beneficial effect of nitric oxide provision
to the kidney has been also ascribed to a reduction of
vascular and renal endothelin-1 (ET-1) synthesis [16, 23].
This latter mechanism is particularly intriguing for PHN,
in that in this model, urinary excretion of ET-1 increased
over time in parallel with proteinuria [24], and renopro-
tection afforded by the combination of ACE inhibitors
and angiotensin II receptor blocker was associated with
remarkable suppression of exuberant renal ET-1 [25].
Here, we studied whether l-arginine, which provides
eNOS with substrate to enhance nitric oxide synthesis,
potentiated the effect of an ACE inhibitor of limiting
renal injury when given to PHN rats with overt nephrop-
athy. We also sought to evaluate whether a possible
renoprotective effect of the combination therapy was
associated with changes in renal ET-1, a possible trigger
of progressive renal injury in this model.
METHODS
Experimental design
Male Sprague-Dawley rats (Charles River Italia s.p.a.,
Calco, Italy) with initial body weights of 275 to 330 g
were used in this study. Animal care and treatment were
conducted in accordance with the institutional guidelines
that are in compliance with national (Decreto Legislativo
n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Cir-
colare n.8, Gazzetta Ufficiale 14 luglio 1994) and interna-
tional laws and policies (EEC Council Directive 86/609,
OJL358-1, December 1987; Guide for the Care and Use
of Laboratory Animals, U.S. National Research Council,
1996). All animals were housed in a room in which the
temperature was kept constant on a 12-hour dark/12-hour
light cycle and allowed free access to standard diet con-
taining 20% protein by weight and tap water. PHN was
induced in nonanesthetized rats by a single intravenous
injection of 0.4 mL/100 g body weight of rabbit anti-
Fx1A antibody. Unilateral nephrectomy at day 7, when
animals are proteinuric, was performed to accelerate the
onset of renal histologic damage [11]. Two months later,
rats were divided into four groups (N  10 each) and
daily treated up to 9 months as follows: vehicle (group 1);
l-arginine (Farmaceutici Damor, Napoli, Italy), 1.25 g/L
in the drinking water (group 2); lisinopril (AstraZeneca,
Basiglio, Milan, Italy), 40 mg/L (group 3); l-arginine,
1.25 g/L, plus lisinopril, 40 mg/L (group 4). An additional
group of normal rats served as control (group 5, N 
6). The dose of l-arginine was selected on the basis of
previous reports documenting renal protection in other
models of renal disease [18, 23]. The dose of 40 mg/L of
lisinopril was chosen because of partial antiproteinuric
effect when administered to PHN rats at an advanced
phase of the disease [26], mimicking the clinical condition
of patients who do not completely respond to ACE inhib-
itors.
Systolic blood pressure, urinary protein excretion, and
serum creatinine were measured at 0, 2 (before treat-
ment), 3, 5, 7 and 9 months. Urinary excretion ET-1 was
assessed at the end of the study. To obtain an indirect
in vivo index of renal nitric oxide synthesis, 24-hour
urinary excretion of cyclic guanosine monophosphate
(cGMP) was measured in all groups at the end of the
study. At 9 months, rats were anesthetized and kidneys
were removed for morphologic analysis.
Systolic blood pressure was recorded by tail plethys-
mography in conscious rats. Twenty-four–hour urine
samples were collected using metabolic cages and pro-
teinuria was determined by modified Coomassie blue G
dye binding assay for proteins with bovine serum albu-
min (BSA) as standard [27]. Blood was collected from
the tail vein of anesthetized animals. Serum was obtained
after whole blood clotting and kept frozen at 20C
until assayed. Serum creatinine was measured by alkaline
picrate method [28].
Urinary ET-1 measurement
Urinary ET-1 levels was evaluated by radioimmuno-
assay (RIA) after extraction with Sep-pak C18 (Waters,
Milford, MA, USA) as previously described [29]. Cross-
reactivity of the ET-1 antibody (Peninsula Laboratories,
Inc., San Carlos, CA, USA) was as follows: ET-2, 46.9%;
ET-3, 17%; and big-ET-1, 9.4%. Results corrected for
the recovery were expressed as picograms per day.
Urinary cGMP excretion
Urinary cGMP levels were determined by commercial
EIA kit (range, 0.5 to 128 pmol/L) (Amersham Phar-
macia Biotech, Buckinghamshire, UK). Data are ex-
pressed as nanomoles per day.
Renal histology
The removed kidneys were fixed overnight in Dubosq-
Brazil, dehydrated in alcohol, and embedded in paraffin.
Kidney samples were sectioned at 3 m intervals and
the sections were stained with Masson’s trichrome, he-
matoxylin and eosin, and periodic-acid Schiff (PAS) re-
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agent. Tubular (atrophy, casts, and dilatation) and inter-
stitial changes (fibrosis and inflammation) were graded
from 0 to 4 (0, no changes; 1, changes affecting less
than 25% of the sample; 2, changes affecting 25% to
50% of the sample; 3, changes affecting 50% to 75%
of the sample; and 4, changes affecting 75% to 100%
of the sample). At least 100 glomeruli were examined
for each animal and the extent of glomerular damage
was expressed as the percentage of glomeruli presenting
sclerotic lesions. All renal biopsies were analyzed by the
same pathologist who was unaware of the nature of the
experimental groups.
Statistical analysis
Data are expressed as mean SE. Data were analyzed
using the nonparametric Kruskal-Wallis test for multiple
comparisons. The statistical significance level was de-
fined as P  0.05.
RESULTS
Systemic parameters
Animals exhibited a normal behavior throughout the
study period. Only one rat with PHN died in the vehicle
group, whereas all rats assigned to the other groups were
alive at 9 months.
Food intake was comparable in control and PHN rats.
The average food intake at month 9 was as follows:
vehicle, 28  1 g/day; l-arginine, 29  2 g/day; lisinopril,
31  1 g/day; l-arginine  lisinopril, 30  1 g/day; con-
trol, 23  1 g/day. All PHN rats gained weight in a
similar manner and at the end of the study body weight
values were comparable (vehicle, 663 19 g; l-arginine,
663  25 g; lisinopril, 647  26 g; l-arginine  lisinopril,
692  17 g). Body weights of control rats were numeri-
cally higher than those of PHN rats, although a statistic
significance was not reached (744  27 g).
Systolic blood pressure
Figure 1 shows the time course of systolic blood pres-
sure. PHN animals were normotensive at 2 months, be-
fore starting treatment (systolic blood pressure, 128 
2 mm Hg vs. control 123 1 mm Hg). Rats given vehicle
exhibited a significant increase in systolic blood pressure
within 5 months [145  3 mm Hg (P  0.01) vs. control
122  4 mm Hg]. At the end of the study, at 9 months,
systolic blood pressure averaged 153  4 mm Hg (P 
0.01) vs. control 121 2 mm Hg. Treatment with l-arginine
alone maintained systolic blood pressure at values sig-
nificantly lower than those of vehicle group, but higher
than controls (132 4 mm Hg) during the entire observa-
tion period. In PHN rats treated with lisinopril alone or
in combination with l-arginine, systolic blood pressure
was reduced to values that were even lower (P  0.01)
Fig. 1. Time course of systolic blood pressure in passive Heymann
nephritis (PHN) rats given vehicle (N 9), L-arginine (N 10), angio-
tensin-converting enzyme (ACE) inhibitor lisinopril (N  10), L-argi-
nine plus ACE inhibitor (N  10), and in control rats (N  6). Data
are mean  SE. P  0.01 vs. control; *P  0.01 vs. vehicle, l-arginine,
and control; P  0.05; P  0.01 vs. vehicle.
than those of control rats (90 4 mm Hg; 80 4 mm Hg,
respectively).
Urinary protein excretion
The time course of urinary protein excretion is shown
in Table 1. In rats with PHN proteinuria progressively
increased with time, with mean values exceeding 350 mg/
day in all groups before treatment (month 2). In rats
given l-arginine proteinuria levels were comparable to
those measured in PHN rats given vehicle. Administra-
tion of ACE inhibitor maintained urinary protein similar
to pretreatment along the whole study period, with val-
ues being reduced on average by 50% in respect to ani-
mals receiving vehicle. By contrast, combining l-arginine
with lisinopril had a powerful antiproteinuric effect, such
that proteinuria values were significantly lower than ve-
hicle (P  0.01). Remarkably, in the combined therapy
group, urinary protein excretion was reversed in respect
to pretreatment, to levels that were not different from
those of age-matched controls.
Renal function
Renal function in PHN rats given vehicle progressively
worsened, as indicated by serum creatinine levels sig-
nificantly higher than controls (Table 2). PHN rats given
l-arginine exhibited high levels of serum creatinine that
were comparable to those of untreated PHN rats. Renal
function impairment was partially ameliorated by lisino-
pril. Actually, mean values of serum creatinine were nu-
merically lower than vehicle, although a statistic signifi-
cance was not achieved. Conversely, in rats on l-arginine
plus lisinopril, serum creatinine levels were comparable
to those measured in the same animals before treatment
and significantly lower than those of vehicle rats.
Renal histology
The results of renal histology are reported in Figure 2.
The percentage of sclerotic glomeruli and the scores of
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Table 1. Time course of proteinuria in passive Heymann nephritis (PHN) rats
Proteinura mg/day
2 (before
Groups 0 treatment) 3 5 7 9 months
PHN  vehicle 202 36567 599107a 62783a 64380a 70962a
PHN  l-arginine 191 35359 54464a 63449a 75347a 74331a
PHN  lisinopril 211 38158 31584a 354103a 342111a,b 355120d
PHN  l-arginine  lisinopril 192 35055 11719a,b 9516c,e 15641c 14342c
Control 232 316 366 438 437 8016
Values are expressed as meanSE.
aP  0.01 vs. control; bP  0.05; cP  0.01 vs. vehicle and l-arginine; dP  0.05 vs. l-arginine; eP  0.01 vs. lisinopril
Table 2. Time course of serum creatinine in passive Heymann nephritis (PHN) rats
Serum creatinine mg/dL
2 (before
Groups 0 treatment) 3 5 7 9 months
PHN  vehicle 0.620.03 0.820.02b 1.080.04b 1.070.04b 1.080.12b 1.960.59b
PHN  l-arginine 0.550.02 0.880.03b 0.920.03b 0.980.04b 1.000.06b 1.800.45b
PHN  lisinopril 0.560.02 0.860.03b 0.850.02b,c 0.880.02b,e 0.890.04b 0.980.05a
PHN  l-arginine  lisinopril 0.630.01 0.840.03b 0.820.03b,c 0.780.02b,d 0.770.04a,e 0.850.05f
Control 0.580.02 0.620.02 0.590.02 0.610.02 0.630.04 0.810.04
Values are expressed as meanSE.
aP  0.05; bP  0.01 vs. control; cP  0.01 vs. vehicle; dP  0.01 vs. vehicle, l-arginine alone, and lisinopril alone; eP  0.05; fP  0.01 vs. vehicle and l-arginine
Fig. 2. Renal morphologic parameters at 9
months in passive Heymann nephritis (PHN)
rats given vehicle (N 9), L-arginine (N 10),
angiotensin-converting enzyme (ACE) inhibi-
tors (N  10), L-arginine plus ACE inhibitor
(N  10), and in control rats (N  6). Data
are mean SE. P  0.05; •P  0.01 vs. con-
trol; P  0.01 vs. vehicle and l-arginine;
*P  0.01 vs. vehicle.
tubular damage and interstitial inflammation were signifi-
cantly increased in untreated PHN rats at 9 months in
respect to age-matched controls. Treatment with l-argi-
nine did not affect the development of glomerulosclero-
sis and tubulointerstitial lesions that were instead sig-
nificantly reduced by lisinopril. Combination of lisinopril
and l-arginine further ameliorated glomerulosclerosis
and tubular damage.
Urinary excretion of ET-1
Urinary excretion of ET-1, taken as an index of renal
synthesis of the peptide [29, 30], was fivefold increased
in PHN rats over age-matched controls at 9 months (Fig.
3), confirming our previous data in the two-kidney PHN
model at 12 months. l-arginine alone reduced urinary
ET-1 by 23%. By contrast, excessive urinary ET-1 was
remarkably reduced by lisinopril alone [40% (P  0.05)
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Fig. 3. Urinary excretion of endothelin-1 (ET-1) at 9 months in passive
Heymann nephritis (PHN) rats given vehicle (N  9), L-arginine (N 
10), angiotensin-converting enzyme (ACE) inhibitors (N  10), L-argi-
nine plus ACE inhibitor (N  10), and in control rats (N  6). Data
are mean  SE. P  0.05; •P  0.01 vs. control; *P  0.05; **P 
0.01 vs. vehicle; #P  0.05 vs. l-arginine.
vs. vehicle] and even to a greater extent by the combined
treatment [62% (P  0.01) vs. vehicle].
Urinary excretion of cGMP
Urinary excretion of cGMP, used as an indirect mea-
sure of nitric oxide, was significantly decreased in PHN
rats compared to controls (Fig. 4). l-arginine slightly
increased urinary cGMP levels that were instead en-
hanced by lisinopril and almost normalized by l-arginine
plus lisinopril treatment.
DISCUSSION
Results from this study demonstrate that in a severe
rat model of PHN, which mimics an advanced phase of
renal disease in humans, adding l-arginine to an ACE
inhibitor had a potent antiproteinuric effect and remark-
ably retarded the progression of renal disease, while
ACE inhibition alone was less effective.
Angiotensin II and bradykinin levels within the vascu-
lar wall are controlled by ACE, which generates angio-
tensin II and catalyzes the hydrolysis of bradykinin into
biologically inactive products [31]. Bradykinin through
stimulation of the B2-receptor subtype induces release
of vasodilating substances, including nitric oxide, from
vessel endothelium. Data are indeed available that ACE
inhibitors, by preventing bradykinin degradation, en-
hance the release of nitric oxide from vascular endothe-
lium and this would translate into defense mechanisms
against hypertension and vascular dysfunction [32–34].
Fig. 4. Urinary excretion of cyclic guanosine monophosphate (cGMP)
at 9 months in passive Heymann nephritis (PHN) rats given vehicle
(N  9), L-arginine (N  10), angiotensin-converting enzyme (ACE)
inhibitors (N  10), L-arginine plus ACE inhibitor (N  10), and in
control rats (N  6). Data are mean  SE. •P  0.01 vs. control; *P 
0.05 vs. vehicle.
Here, we found that in PHN, defective renal nitric
oxide documented by low urinary cGMP excretion, can
be partially restored by lisinopril, while normalized by
adding l-arginine to the ACE inhibitor. A previous study
in PHN model showed that urinary cGMP started to de-
cline as early as 6 weeks after disease induction [13]. Capto-
pril administered concomitantly with the immune insult
enhanced cGMP excretion, indicating that dysfunctional
nitric oxide system is blunted by ACE inhibitors. In the
remnant kidney model characterized by impaired renal
synthesis of nitric oxide, chronic administration of the
nitric oxide donor, molsidomine, decreased blood pres-
sure, partially reduced proteinuria and renal dysfunction,
with an effect even higher than lisinopril at an early stage
of the disease, suggesting a key role of renal nitric oxide
in the early development of the lesions [35]. Beside a
direct effect on determinants of renal injury via nitric
oxide, molsidomine may also attenuate the damage by
limiting renal ET-1, given the fact that in the remnant
kidney model nitric oxide donor [35] has a well-docu-
mented capacity of modulating ET-1 pathway. In kidneys
of rats with PHN, expression of ET-1 mRNA and synthe-
sis of the corresponding peptide were dramatically in-
creased and strongly localized in proximal tubules and
in mononuclear inflammatory cells infiltrating the renal
interstitium [25]. Excess synthesis of ET-1 in proximal
tubules in proteinuric rats with PHN could derive from
the continuous protein overreabsorption that occurs in
vivo as a consequence of enhanced glomerular protein
trafficking. Relevant to this interpretation are in vitro
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data showing that proximal tubular cells in culture ex-
posed to albumin or other proteins at concentrations
comparable to those in proximal tubular fluid of protein-
uric animals synthetize and release an excessive amount
of ET-1 [36]. Moreover, in various experimental models
of progressive renal injury, enhanced renal synthesis of
ET-1 correlates with the severity of renal damage, and
pharmacologic manipulation of the ET pathway retards
the rate at which renal function is lost, and also prolongs
animal survival [37, 38]. That both ET-1 and angiotensin
II conspire to promote renal damage in animals is consis-
tent with previous findings that a combination of an ACE
inhibitor and an unselective ET-1 receptor antagonist
had an unequivocal antiproteinuric effect and protected
against deterioration of renal function, while each drug
alone was remarkably less effective [11]. These findings
support the value of simultaneously interrupting dispa-
rate mediators of injury to effectively slow progression of
proteinuric nephropathies, particularly in advanced dis-
ease. Along this line, in the present study, adding l-argi-
nine to lisinopril was more effective in respect to single
agents in limiting proteinuria and progression, which was
paralleled by a significant reduction of ET-1. Actually,
l-arginine failed to ameliorate renal dysfunction and lisi-
nopril had only a partial protective effect. Previous stud-
ies showed that dietary supplementation with l-arginine
ameliorated renal function and limited renal structural
injury and interstitial infiltration of inflammatory cells
in experimental models of progressive nephropathies,
including subtotal nephrectomy and ureteral obstruction
[16–18, 21]. The discrepancy with results presented here
can be explained by the different starting time of the
amino acid administration and/or the severity of the
model used. A remarkable feature of the combined ther-
apy is represented by its antihypertensive action mainly
sustained by lisinopril. It is well known that control of
systemic blood pressure by ACE inhibitors translates
into a reduction of intraglomerular hypertension, possi-
bly due to the property of this class of drugs of reducing
efferent arteriolar resistance [39]. In this context, the
association of l-arginine, which increases nitric oxide
availability, to ACE inhibitors would possibly contribute
to the amelioration of glomerular hemodynamics. On
the other hand, l-arginine might have renal effects inde-
pendent of the generation of nitric oxide. In normal
animals and humans, the intravenous administration of
amino acids causes significant changes in renal hemody-
namics as a result of a combination of local factors,
including their direct vasodilatory effect or the induction
of vasoactive hormones, and the release of the growth
hormone and glucagone in the systemic circulation [40].
CONCLUSION
The present study showed that in a severe model of
progressive nephropathy only partially responsive to
ACE inhibitor, combining l-arginine with lisinopril re-
versed proteinuria and protected against renal function
impairment. Possible targets of the combined agents’
action are the glomerular permselective dysfunction and
secondary pathways of damage triggered by nitric oxide
and ET-1, which contribute to perpetuate renal injury
in accelerated PHN. The proposed therapeutic approach
could add to the available armamentarium for patients
with advanced renal disease in which ACE inhibitors
alone fail to prevent progressive renal injury.
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